A Prospective, Split-Face, Randomized Study Comparing a 755-nm Picosecond Laser Full Beam vs. Combined Full and Fractional Beam in the Treatment of Melasma in Asians.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250801004

Enrollment

Registered

2025-08-01

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma Melasma

Interventions

Patients were treated by using a 755-nanometer picosecond laser with full Beam mode on facial melasma. Treatment will be administered to a randomly assigned side of the face. A total of five treatment

Experimental Device,Experimental Device

755-nm Picosecond Laser Full Beam,755-nm Picosecond Laser Combined Full and Fractional Beam

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and older, of both male and female genders. 2. Asians with Fitzpatrick Skin Type IV-V. 3. Diagnosed with melasma by medical professional. 4. Patients with melasma lesions on both sides of the face. 5. Patients who voluntarily consent to participate in the study and agree to undergo laser treatment at the specified sites according to the research methodology.

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant or breastfeeding. 2. Patients with a dermatitis on the face. 3. Patients with a history of using hormones or birth control pills within the past 3 months. 4. Patients who have undergone facial laser treatment within the past 6 months. 5. Patients who have received topical or oral medication for melasma treatment within the past 3 months. 6. Patients who have undergone facial laser treatment for melasma within the past 3 months. 7. Patients with a diagnosed psychiatric disorder, confirmed by a psychiatrist. 8. Patients who do not consent to having their photos taken for treatment evaluation purposes.

Design outcomes

Primary

Measure	Time frame
melanin concentration baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. antera 3D, Melanin and erythema index baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. mexameter	—

Secondary

Measure	Time frame
Physician improvement scale baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. Quartile scale,modified Melasma Area Severity Index score baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. modified Melasma Area Severity Index score,Patient improvement scale baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. Quartile scale	—

Measure

Time frame

Physician improvement scale baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. Quartile scale,modified Melasma Area Severity Index score baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. modified Melasma Area Severity Index score,Patient improvement scale baseline, 1 month after 3rd treatment, 1, 3 and 6 months after complete the treatment. Quartile scale

—

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital, Mahidol University

woraphong.man@mahidol.ac.th66819150555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026